Saturday 17 October 2026 Export DNTH’s income statement to Excel — free account

Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024. In the quarter to June 2026, revenue grew 294.3%, EPS fell 2.27% and free cash flow fell 105.4%, each against the same quarter a year earlier.

72.09 2.44 −3.27%

Follow DNTH

Alert me

Market cap: $4.2B
P/E: 0.0×
Fwd P/E: −21.5×
Dividend yield: —
F-score: 2/9
Altman Z: 24.31
Beneish M: −4.75
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 71.20

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	—	—	6	1	1	2	1	5	2	—

Insider Ownership 16.99%

Capital & Financial Ratios $m

Market Cap 4,170.00

Revenue 1.90

Net Income (192.25)

Free Cash Flow (155.71)

Net Debt (886.81)

Current Ratio 26.10

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (21.50)

P/S ratio 2,121.40

P/B ratio 3.45

Past 5Y EPS Growth —

This Y EPS Growth 9.76%

Next Y EPS Growth (20.66%)

Next Y revenue growth (8.15%)

Next 5Y EPS Growth (10.19%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 83.33%

10-year low 10-year high

P/B against its own 10 years 82.71%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	174	275	404	887
Receivables	0	1	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	177	281	409	898

	2023	2024	2025	Q'26
Payables	3	5	10	6
ST’ Debt	—	—	—	—
Other	—	—	—	—
	10	18	31	34

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(31.80%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	27.95%	88.51%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	1	—	—	—
’25	1	0	0	0	2
’24	1	2	2	1	6
’23	0	1	1	0	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(29)	(49)	—	—	—
’25	(28)	(24)	(31)	(47)	(129)
’24	(15)	(15)	(21)	(27)	(78)
’23	(10)	(5)	(10)	(12)	(37)
’22	(20)	(17)	16	(9)	(29)
’21	(17)	(13)	(14)	(16)	(60)
’20	(17)	(19)	(14)	(14)	(64)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(29)	(49)	—	—	—
’25	(28)	(24)	(31)	(47)	(129)
’24	(15)	(15)	(21)	(27)	(78)
’23	(10)	(5)	(10)	(12)	(37)
’22	(20)	(17)	16	(9)	(29)
’21	(17)	(13)	(15)	(16)	(61)
’20	(17)	(19)	(14)	(14)	(64)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.85)	(0.90)	—	—	—
’25	(0.82)	(0.88)	(0.97)	(1.43)	(4.20)
’24	(0.54)	(0.51)	(0.74)	(0.81)	(2.55)
’23	(8.10)	(12.73)	(3.78)	(0.71)	(8.45)
’22	(6.24)	(4.64)	(8.90)	(12.74)	(32.58)
’21	(5.76)	(5.12)	(4.80)	(5.28)	(20.64)
’20	(8.16)	(7.68)	(5.92)	(6.08)	(27.36)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	84.96	86.56	92.16	70.40	5.12	5.92	10.22	13.37	Analyst estimates 2026–2028 Powerpack
	High	—	—	261.28	336.00	254.40	227.20	87.84	14.40	33.77	45.46
People
People	Employees	—	48	59	72	69	75	67	53	78	92
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.00	0.10	0.05	0.08	0.02
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	6	3	6	2
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
	EBT	(9)	(35)	(58)	(77)	(75)	(71)	(28)	(44)	(85)	(162)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	(443.76)	(1,541.22)	(1,362.77)	(7,973.33)
	Net income	(9)	(35)	(58)	(77)	(75)	(71)	(28)	(44)	(85)	(162)
	Depreciation	0	0	1	2	2	2	0	(1)	(6)	(6)
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	7.34	0.55	0.19	0.05
	Earnings	(1,009.92)	(305.81)	(50.08)	(33.12)	(27.36)	(20.64)	(32.58)	(8.45)	(2.55)	(4.20)
	Cash flow	(702.04)	(191.76)	(36.44)	(24.68)	(23.32)	(17.33)	(33.26)	(7.15)	(2.35)	(3.34)
	Capex	(14.95)	(18.94)	(6.66)	(1.32)	(0.15)	(0.37)	(0.16)	(0.02)	0.00	(0.01)
	Free cash flow	(716.99)	(210.70)	(43.11)	(26.01)	(23.47)	(17.70)	(33.42)	(7.17)	(2.35)	(3.35)
	Book value	(954.19)	(362.77)	126.73	61.03	52.42	50.28	84.27	32.77	10.58	12.78
	Shares, m	0	0	1	2	3	3	1	5	33	39
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	0.00	20.88	116.48	781.65
	P/B	—	—	—	—	—	—	0.00	0.35	2.06	3.23
	EV/Sales	—	—	—	—	—	—	0.00	(40.59)	72.33	583.07
	EV/FCF	—	—	—	—	—	—	2.39	3.10	(5.76)	(9.18)
Cash, $m
Cash, $m	Operating cash flow	(7)	(22)	(42)	(57)	(64)	(60)	(29)	(37)	(78)	(129)
	Capex	0	(2)	(8)	(3)	0	(1)	0	0	0	0
	Free cash flow	(7)	(24)	(50)	(60)	(64)	(61)	(29)	(37)	(78)	(129)
Balance, $m
Balance, $m	Working capital	9	48	135	136	140	170	74	168	262	379
	Total debt	—	—	—	—	—	—	30	—	—	—
	Net debt	(5)	(52)	(143)	(146)	(149)	(177)	(75)	(174)	(275)	(404)
	Shareholders’ equity	(9)	(42)	146	141	144	173	74	169	352	493
Returns, %
Returns, %	ROA	(29.59)	(107.92)	(54.40)	(48.16)	(46.38)	(40.47)	(20.86)	(33.18)	(30.71)	(35.88)
	ROIC	0.00	0.00	(1,217.57)	0.00	0.00	0.00	0.00	0.00	(82.43)	(124.80)
	ROE	38.18	139.26	(111.28)	(53.53)	(52.57)	(44.94)	(44.39)	(69.97)	(32.60)	(38.38)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DFTX Definium Therapeutics, Inc.	$4.6B	— (loss-making)	—	—	n/m	−78.31% (below 0%: shrinking)	0.00%	0.00%	Compare
DNTH Dianthus Therapeutics, Inc.	$4.2B	— (loss-making)	— (loss-making)	+294.30% (above 0%: growing)	n/m	−105.37% (below 0%: shrinking)	100.00%	(8,079.11%)
EWTX Edgewise Therapeutics, Inc.	$4.2B	— (loss-making)	—	—	n/m	−30.24% (below 0%: shrinking)	0.00%	0.00%	Compare
ABCL AbCellera Biologics Inc.	$4.1B	— (loss-making)	— (loss-making)	−76.29% (below 0%: shrinking)	n/m	+151.98% (above 0%: growing)	100.00%	(1,550.05%)	Compare
LEGN Legend Biotech Corporation Sponsored ADR	$3.8B	— (loss-making)	112×	+51.90% (above 0%: growing)	n/m	−26.79% (below 0%: shrinking)	64.54%	14.37%	Compare
TNGX Tango Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−4.58% (below 0%: shrinking)	0.00%	0.00%	Compare
RLAY Relay Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−95.44% (below 0%: shrinking)	n/m	+2.13% (above 0%: growing)	100.00%	(25,949.71%)	Compare
ARQT Arcutis Biotherapeutics, Inc.	$3.7B	131×	196×	+59.33% (above 0%: growing)	n/m	+227.96% (above 0%: growing)	91.58%	12.65%	Compare
TLX Telix Pharmaceuticals Limited	$3.6B	—	—	—	—	−44.78% (below 0%: shrinking)	—	—	Compare
Median of peers	$3.8B	—	—	−76.29%	—	−15.69%	64.54%	0.00%

All 614 Biotechnology stocks →

Dianthus Therapeutics, Inc. (DNTH) key facts

Concern: Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
Dianthus Therapeutics, Inc. (DNTH) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DNTH traded at $72.09, a market capitalization of $4.2 billion.
Return on equity was −38.4% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 24.31 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.